Benefits
Less time awake during the night (meta-analysis finding)
The clearest pooled finding comes from a 2022 systematic review and meta-analysis of tryptophan sleep trials: doses of roughly 1 g or more significantly reduced wake after sleep onset (WASO) — the time spent awake during the night — but did not significantly improve the other sleep components measured, including how long it took to fall asleep. Older, much smaller sleep-laboratory studies did report increased sleepiness and shorter sleep latency, but that result did not hold up when the trials were pooled, so "less time awake in the night" is the honest summary rather than "falls asleep faster". The effect is mediated by serotonin's role in sleep initiation and tryptophan's direct conversion to melatonin in the pineal gland.
Mood support — what the reviews actually show
A systematic review of L-tryptophan supplementation and mood reported improvements in mood and emotional functioning, most consistently under stress or where baseline tryptophan intake was low; the underlying trials are generally small and short. Separately, rapid tryptophan depletion research — an inverse design that lowers tryptophan rather than supplementing it — shows that depleting tryptophan worsens mood and sleep EEG. That is strong evidence for the serotonin pathway's role, but it is not evidence that supplementation treats depression. Depression is a diagnosed medical condition; anyone considering tryptophan for low mood should involve a clinician, particularly if already taking a serotonergic medication. Effects are most pronounced in individuals with low baseline tryptophan status.
Appetite pathway (mechanism, not demonstrated here)
Serotonin signalling in the hypothalamus is part of how the body regulates appetite and satiety, and tryptophan is the substrate for that serotonin. This is a mechanism rather than a demonstrated outcome here: none of the human studies cited on this page measured food intake, satiety ratings, cravings or body weight, so tryptophan should not be assumed to reduce appetite or support weight loss.
PMS mood symptoms improvement
In one placebo-controlled trial in women with premenstrual dysphoric disorder (PMDD) (Steinberg 1999), L-tryptophan at 6 g/day taken during the luteal phase reduced dysphoria, irritability and tension scores compared with placebo. Important context: this is a single, older trial at a research-level dose far above typical supplement use, in a diagnosed psychiatric condition — PMDD is not the same as ordinary premenstrual discomfort. Serotonin signalling is one proposed mechanism in premenstrual mood symptoms, but the trial does not establish that tryptophan corrects a deficiency. PMDD is a medical diagnosis with first-line treatments that have much stronger evidence, so this is a clinician-supervised decision rather than a self-treatment recommendation.
Mechanism of action
Serotonin synthesis via 5-HTP intermediate
Dietary tryptophan crosses the blood-brain barrier via the large neutral amino acid (LNAA) transporter and is converted to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase (TPH), then to serotonin by aromatic L-amino acid decarboxylase (AADC). Brain serotonin levels directly influence mood, appetite, pain sensitivity, and sleep architecture.
Melatonin synthesis in the pineal gland
In the pineal gland, serotonin is N-acetylated to N-acetylserotonin, then methylated to melatonin by HIOMT. This tryptophan-serotonin-melatonin pathway is exclusively responsible for endogenous melatonin production — explaining why tryptophan supplementation improves both mood (via serotonin) and sleep (via melatonin).
Kynurenine pathway competition
The majority of dietary tryptophan (90–95%) is metabolized via the kynurenine pathway rather than serotonin synthesis. Inflammation activates IDO (indoleamine 2,3-dioxygenase), diverting more tryptophan to kynurenine and away from serotonin — a mechanism linking chronic inflammation to depression. It has been proposed that supplemental tryptophan could help maintain substrate for the serotonin pathway when kynurenine activity is elevated, but that is a hypothesis — none of the studies cited here tested whether supplementation changes this balance or the outcomes attributed to it.
Clinical trials
Early sleep-laboratory research on the effects of L-tryptophan given at bedtime on sleepiness and on sleep (Hartmann, 1982; PMID 6764927). This is small, early-era work that predates modern trial-reporting standards, and its results should be read alongside the later pooled meta-analysis rather than in place of it.
15 healthy adults with mild insomnia.
This early work reported increased sleepiness and shorter time to fall asleep with L-tryptophan taken at bedtime. Important caveat: the later 2022 systematic review and meta-analysis pooling tryptophan sleep trials did NOT find a significant effect on time to fall asleep — the significant finding there was less time awake after sleep onset, at doses of 1 g or more. Treat this older single-study result as historical context, not as the current best estimate. Critical cautions: (1) eosinophilia-myalgia syndrome (EMS) — 1989 outbreak (>1,500 cases, 38 deaths) traced to L-tryptophan from a single Japanese manufacturer (Showa Denko) producing impurities ('Peak E'); led to FDA ban 1989-2005; (2) modern status — pharmaceutical-grade L-tryptophan now permitted with enhanced quality controls; (3) BUYER caution — some products may have impurity concerns; verify pharmaceutical-grade source.
Randomized, double-blind, placebo-controlled trial of L-tryptophan 6 g/day taken during the luteal phase versus placebo in women with premenstrual dysphoric disorder (PMDD), run across three menstrual cycles. (Steinberg et al. 1999, J Psychiatry Neurosci)
Women meeting diagnostic criteria for premenstrual dysphoric disorder (PMDD) — a diagnosed condition, not a general-wellness population, so the result does not transfer to everyday premenstrual discomfort.
Tryptophan reduced dysphoria, irritability and tension scores compared with placebo. This is one trial at a research-level dose (6 g/day) and has not been replicated at scale; the serotonin route is the proposed mechanism rather than a measured one. Note: SSRIs (fluoxetine, sertraline) are first-line for PMDD with strong evidence; tryptophan adjunctive at most.